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EVALUATION OF AIR TRANSPORTATION UNDER CONTROLLED 
ROOM TEMPERATURE FOR PHARMACEUTICALS
ABSTRACT
Pharmaceutical industry like aviation is one of the most 
regulated industries today. Shipping pharmaceutical prod-
ucts under defined time and temperature conditions is a 
challenge deriving from regulatory and product quality as-
pects. Good distribution practice should be valid throughout 
the distribution chain but regulatory issues are still short of 
strength in practice. Transportation should be considered 
as extended warehousing, still compliances are business 
rather than regulatory driven. The paper demonstrates devi-
ations between shipping requirements and realistic capabili-
ties of today’s commercial aviation in terms of maintenance 
of the controlled room temperature. Examples show cases 
of temperature deviations during transport realization. Sug-
gestions are made on future research in the field of air trans-
portation.
KEY WORDS
good distribution practice, regulatory issues, controlled room 
temperature, temperature deviations, process qualification
1. INTRODUCTION
In order to secure pharmaceutical product’s origi-
nal quality during its validity period, it is essential to 
secure storage and distribution under specified condi-
tions. These conditions comprise predefined storage 
and distribution temperatures, level of humidity and 
protection against light exposure. While primary pack-
aging protects the product from moisture and light, 
shipments of pharmaceuticals might get exposed 
to atmospherics conditions during distribution. This 
makes temperature major constrain in securing and 
defining the appropriate traceability process [1]. Ware-
housing and transportation processes need to be de-
signed in such a way to secure the product from any 
temperature exposures outside the defined regimes in 
which product stays in its original quality thus protect-
ing the end users’ health.
Distribution chains are very often a set of complex 
processes which include several stakeholders and lo-
cations [2, 3]. Regulatory issues to be complied with 
emphasize further its complex structure. Logistical 
support only could comprise more than one stake-
holder even in a point-to-point distribution scenario. 
Transportation companies as well as handling termi-
nals further deepen this structured pattern. Simple 
distribution pattern consists of producer to consumer 
distribution realization. However, this mode of distribu-
tion is seldom the case. Far more often a scenario con-
siders a process which includes several warehouses, 
some at remote sites with shorter or longer storage 
processes, handling terminals, different transporta-
tion modes, integral or multimodal solutions, waste 
number of manipulations from fully automated to 
hand manipulation thus generating a set of complex 
and design-demanding processes.
Additional complexity of distribution processes is 
emphasized by the diversity of transport models as 
well as the capability of adaptation to controlled tem-
perature conditions. Transportation means are se-
lected according to the volumes and routes planned. 
Road transportation, where available and plausible, 
using cool trucking presents a good solution in the 
preservation of a defined temperature regime. Sea 
freight might be accounted for where low costs for 
shipping are prerequisite and time-defined shipping is 
not a must, but the transport mode changes in reach-
ing the port of departure remain the critical point in 
realization. Graph 1 presents a relationship between 
time consumed by transportation processes and costs 
related to different transportation modes. Shipping 
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by air proves to be difficult in terms of securing the 
required temperature regimes or at least the costs of 
applying safe models are the highest. Still, this means 
of transportation stays in focus of pharmaceutical in-
dustry in long-range shipping solutions due to its ca-
pability of covering high distances in the shortest pos-
sible time, thus safeguarding the goods from being in 
distribution for a long period of time (sea freight might 
take four weeks between Europe and North Atlantic). 
Air and sea modes presented by the graph consist not 
only of one transportation means and service provider. 
Allocation of the goods in the sea or air ports still com-
prises trucking in most of the cases but does not mean 
automatically a multimodal transportation solution.
2. REGULATORY ISSUES IN 
TRANSPORTING PHARMACEUTICALS
The pharmaceutical industry is one of the most 
regulated industries in the globalized world market to-
day. Effects of globalization resulted in the need for 
even stricter regulations in distribution thus aiming to 
harmonize standards for good manufacturing, storage 
and distribution practices [4, 5]. Pharmaceutical prod-
uct shall be kept under the prescribed temperature, 
humidity and light conditions during storage and distri-
bution thus preserving the original quality of the prod-
uct throughout the distribution channels [6, 7, 8]. This 
requirement is today in the focus of all the national 
and international regulatory bodies.
The most important milestones in the United 
States of America regulative in the field of pharmaceu-
tical products distribution are contained in the USP1 
document General Chapter 1079 Good Storage and 
Shipping Practice. The document consists of stan-
dards and defined procedures in the field of medicinal 
products distribution accepted by the FDA2 [9]. This 
USP document publishes the results of research in the 
field of storage processes for pharmaceuticals, valida-
tion of transport means and applicable distribution 
processes. Good Storage and Shipping Practices de-
veloped by the USP is directed through this document 
towards manufacturers, distributors, wholesalers, 
package producers and transport logistics providers 
[10]. It also comprises risk analysis in the distribution 
of time and temperature sensitive pharmaceuticals re-
lated to the effects of temperature, humidity and vibra-
tion exposures and defines the conditions for distribu-
tion from the producer to the end user. The document 
carries out the obligation which all involved stakehold-
ers have towards the shipping requirements defined by 
the producer. The processes defined to address these 
requirements are generally considered as Cool Chain 
Management3.
The European regulation issues are related to the 
production and distribution of medicinal products as 
stipulated by the EMEA4. The Agency produced and 
published a series of documents which regulate the 
obligations and liabilities of all the participants in the 
distribution chain for medicinal products [11, 12]. The 
recommendations about Good Distribution Practice5 
account the conditions under which the transport of 
pharmaceuticals should be performed with a partic-
ular emphasis on the indication of unacceptable de-
grees of heat, cold, light, moisture or other adverse 
influences. Those pharmaceuticals which require 
controlled temperature storage should also be trans-
ported by specialized means in order to appropriately 
and successfully address those requirements. Several 
documents address those issues in particular [13]. 
The Directive 2001/83/EC accounts for wholesale 
distribution chain. Directive 2004/93/EC as well as 
Directive 91/356/EEC contain the principles and rec-
ommendations on good production practice for medic-
inal products. Guidelines on good distribution practice 
of medicinal products are included in Document 94/C 
63/03.
Regulatory issues related to GMP (Good Manu-
facturing Practice), GSP (Good Storage Practice) and 
GDP (Good Distribution Practice) for pharmaceutical 
products in the Republic of Croatia have been regu-
lated by the Law on Medicines6 which in the section 
General Provisions Article 2 defines the GMP as part 
of the quality assurance system which provides conse-
quent and permanent manufacturing and checking ac-
cording to adequate quality standards in compliance 
with their purpose [14, 15]. GDP has been defined as 
a standard for the wholesale storage and transport 
which include organization and conduction of the pro-
cesses in compliance with the required conditions. Al-
though the aforementioned law does not explicitly deal 
with the transport of medicals, the regulatory docu-
ment dealing with GDP7 states those products shall 
be transported in a way in which their identification 
is not lost, contamination is avoided, the breakage, 
leak or spilling does not occur, the goods are safe from 
temperature, humidity and light exposures or patho-

















Diagram 1 - Time spent in distribution related to costs
for different types of transportation modes
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gen contamination. The products which have defined 
storage temperature must be transported according to 
the prescribed temperature regimes. Those conditions 
must be monitored and recorded. The manufacturers 
or distributors included in pharmaceuticals distribu-
tion are obliged to report in writing on any irregularity 
related to drug distribution that might affect its original 
quality as defined in the approved resume on drug’s 
properties according to the Regulation defined for drug 
quality monitoring.
Each of the aforementioned definitions as laid 
down by the respective authority considers transport 
as an inseparable part of both good manufacturing 
and good distribution practice for pharmaceuticals. 
The need to design package and distribution process-
es capable of responding to strict regulatory conditions 
as well as specific characteristics of the transportation 
entity in terms of its sensitivity to various influences 
present in the distribution environment, remains the 
fundamental compliance task for the industry in gen-
eral. Engaged stakeholders are expected to safeguard 
the product while in their custody by setting a number 
of transparent, defined and qualified processes.
The product stability data is basic information re-
quired to define the conditions under which the prod-
uct remains in its original quality and effective until the 
predefined expiry time. This data comprises elevated 
levels of temperature and humidity as stipulated in 
guidelines issued by CHMP8 and ICH9. The results of 
accelerated and stressed tests on stability, including 
but not limited to MKT10 should be used in stability 
studies to cover the real ambient temperature values 
under which the product is preserved in warehouses, 
hospitals, pharmacy or at the end users’ and in drug 
stores [16]. This data should be displayed on the prod-
uct and packing label. Based on the data collected 
during the stability studies for each product, preserva-
tion conditions are evaluated and defined. These con-
ditions are being regularly rechecked and confirmed 
by the regulatory agency as part of registration pro-
cess the product is undergoing on a particular market.
Conditions under which the products are stored or 
distributed (including but not limited to transportation) 
are proven using the calibrated data loggers11 Cool 
trucks might have data loggers preinstalled while in 
air and multimodal transportation cases, devices are 
placed on the packaging or inside the packaging it-
self. The accuracy of the instruments must be ±0.5°C. 
Unlike other parts of GMP, the distribution processes 
are exempt from validation. This fact derives from the 
character of distribution process explained earlier in 
the paper. The USP 1079 document in chapter Con-
trolled Room Temperature, 9th supplement on Good 
storage and shipping practice, defines the preserva-
tion conditions which can be displayed on the prod-
uct label. Most common conditions found on labels 
for tablets, capsules and other oral use substances 
is controlled room temperature. Unlike the ambient 
conditions which are considered as conditions pres-
ent at the working place, the controlled room tempera-
ture comprises more strict range of temperatures from 
+20°C to +25°C. Since the maintenance of such a 
narrow regime is difficult to achieve, approved devia-
tions are defined allowing temperature fluctuations to 
occur in a wider range (+15°C to +30°C). In this case 
an MKT is calculated. If the gained values are within 
the defined regime of +20°C to +25°C, the goods are 
considered to be safe. No report on the temperature 
deviation occurrence is required; no investigation on 
the product quality will take place. Equally, should the 
temperature reach +40°C but over a period shorter 
than 24 hours, or goods were subjected to exposures 
outside the +20°C to +25°C regime for more than 24 
hours, but within the +15°C to +30°C regime all this 
time, the goods will be considered safe from harm.
The mean kinetic temperature is the calculated 
temperature which simulates the influence of different 
temperature deviations the product was subjected to 
during the monitoring period (storage and/or distribu-
tion). MKT represents isothermal temperature which 
simulates the effect of the real temperature within the 
observation period.





















In this formulation HD  represents activation en-
ergy (typically from 60 to 100 kJ/mol for solids and liq-
uids) in this case it is assumed its value is 83.144 kJ/
mol. The R is universal gas constant and its value is 
8.314472 kJ/mol. The temperature T1 is the average 
temperature in degrees Kelvin during the first time 
period. The T2 is the average temperature in degrees 
Kelvin during the second time period and Tn the aver-
age temperature in degrees Kelvin during the nth  time 
period. In this calculation it is assumed that intervals 
of data collection are identical during the observation 
period.
3. ANALYSIS OF TRANSPORT PROCESSES
The paper deals with a particular transportation 
in shipping pharmaceutical products from the ware-
house in Zagreb, Croatia to the distribution center for 
the US market in Forest, Virginia. Commodity is bulk 
prepared tablets which need to be transported under 
controlled room temperature (agreed shipping temper-
ature regime +15°C to +25°C). Transportation con-
sists of trucking to and from the airport of origin and 
final destination and air transportation on Vienna, AT 
– Washington, US route. The average size of the ship-
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ment is 30 euro wooden pallets wrapped with nylon for 
additional protection. Each shipment is accompanied 
with two data loggers activated at the shipper’s ware-
house and deactivated at the consignees warehouse 
thus securing monitoring during the entire trip. Post 
realization analysis of the collected data is a prerequi-
site for the drug release process. A total of nine ship-
ments was analyzed during the period from November 
2009 till the end of January 2010. The evaluation 
consists of data collected from 18 data loggers. Graph 
4.1 shows temperature records of all the shipments 
accomplished in that period. Temperature deviations 
are identified showing mainly lower than allowed tem-
perature records.
Different sections in Figure 1 (marked by numbers 
from 1 to 7) show records through specific phases in 
the transport process. The complete technological pro-
cess can thus be divided into seven different phases or 
characteristic milestones of the process. Each of them 
can be observed separately since it consists of char-
acteristic logistic and transportation processes. The 
first phase (Figure 1 – section 1) is listed under number 
1 in Table 1. The second phase, section 2 in Figure 1 
is the storage process at Vienna International Airport 
in Austria listed under number 2 in Table 2 and so on. 
Trucking on route from Zagreb Airport to Vienna Airport 
is performed using cool trucks with a set temperature 
at +20°C. The trucking to Vienna Airport comprises the 
short time between offload deadline and warehouse po-
sitioning (as per agreement between shipper and car-
rier) in order to minimize exposures which might occur 
during the warehouse storage at Vienna Airport. There 
is no controlled room temperature storage available at 
Vienna Airport. The total time spent between the truck 
offload and the aircraft loading is 11.5 hours. Approxi-
mately 4 hours positioning of the shipment prepared 
on the build unit load device12 in the handling zone of 
the aircraft is included in this period. Total flight time 
might depend on the aircraft on route, weather condi-
tions, total payload on the aircraft and route conges-
tion. Published total flight time on this route for the par-
ticular carrier observed is 9 hours and 45 minutes. The 
offload process at the airport of final destination takes 
4 hours after which the goods are stored in controlled 
room temperature provided by the refer positioned in 
the airport warehouse. During the storage, FDA and 
customs clearance is performed. Total transportation 
time which includes storage is 128 hours during which 
data were collected in 15-minute intervals.
Since there were considerable temperature devia-
tions recorded depending on the phase of the process, 
each of the phases as listed in Table 1 was separately 
analyzed in order to evaluate the potential risk related 
to each phase.
The Zagreb – Vienna part of the route is operated 
by cool trucks. Temperature set-up is +20°C. Figure 2 
shows some deviations occurring in the batch picture 
of all records, but those were of short duration and re-
lated to the door opening for operational reasons (cus-
toms inspection). The average recorded temperature 
was +17.8°C and standard deviation 1.4°C. The re-
cord obtained during the observed period shows rela-
tive stability of temperature within the defined regime 
thus marking this phase of the process as a stable one 
with acceptable level of variation. Red broken lines in 
Figure 2 represent the temperature margin for 95% of 
all transportations. Having the lower margin at around 

















































Route 1 2 3 4 5 6 7
Scatterplot - temperature record for total route
Figure 1 - Batch temperature record of all data loggers analyzed during the observed period
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cess does not represent high risk in temperature de-
viations. If the 17th hour is analyzed in particular as the 
one with the highest deviation, the value of standard 
deviation is 1.8°C which may lead to a conclusion that 
there is high level of certainty the goods will not be 
exposed to the threatening temperature deviations. 
Moreover, the duration of deviations recorded proved 
to be short.
The second phase of the transportation process 
takes place at Vienna Airport. Transit airport Vienna 
does not have the infrastructure designed for stor-
age under controlled temperature regime; however, it 
might be expected that indoor storage would provide 
sufficient protection to safeguard the shipment from 
environmental atmospheric conditions. Figure 3 shows 
the record of all shipments realized in the observed pe-
riod. The average recorded temperature was +18.7°C 
with standard deviation of 1.9°C which is within the 
requested temperature regime.
The third phase of the process as described in Table 
1 accounts for the processes related to the loading of 
the aircraft at Vienna Airport. Those might be consid-
ered as the most critical ones due to the fact that the 
prepared shipment is exposed to severe atmospher-
ic conditions present at the apron. The shorter this 
process is the lesser is the danger the goods will be 
harmed by the atmospheric influences.
As presented in Figure 4, the temperature is drop-
ping every hour by 3.4°C on the average while the low-
er margin of the reliability is dropping towards +12°C. 
The average recorded temperature is somewhat lower 
than in sequences observed earlier +16.4°C, but with 
acceptable value of 1.9°C in standard deviation. Most 
significant deviations occur during the 51st hour where 
the average temperature recorded is +15.6°C with the 
standard deviation of 2.0°C. However, these values 
still demonstrate high level of probability the goods 
will be exposed to the acceptable levels of deviations 
during this phase.
The fourth phase or sequence of the process rep-
resents recorded conditions during the flight on route 
from Vienna to Washington. Despite the fact that a 
Table 1 – Route details including share of different transportation mode
Part of the route Duration13 (h) Cumulative (h)
1 Trucking Zagreb - Vienna 32 32
2 Vienna Airport warehouse 17 49
3 Loading of aircraft (goods positioned for loading) 4 53
4 Flight Vienna - Washington 10 63
5 Positioning in Washington airport warehouse 4 67
6 FDA and customs import clearance 25 92
7 Delivery to the consignee’s warehouse in Virginia 36 128




















1 part of the route
Temp [°C] = 17.6896+0.0079*x; 0.95 Predicted Interval
st
Figure 2 – Temperature records on Zagreb – Vienna route operated cool trucksby
G. Badurina, Z. Majić, S. Pavlin: Evaluation of Air Transportation under Controlled Room Temperature for Pharmaceuticals
126 Promet – Traffic&Transportation, Vol. 23, 2011, No. 2, 121-130
constant temperature drop has been recorded, its 
value of 0.1°C does not represent a significant impact 
since the cumulative value of 1°C might be recorded 
during the flying time. Aircraft on route was equipped 
with a system for maintenance of temperature but the 
accuracy of the temperature regime depends on the 
outside temperature the aircraft was exposed to dur-
ing the loading process as well as on the profile of oth-
er load planned in the same aircraft hold. It has been 
noticed that the position within the hold itself plays an 
important role in maintaining a desired temperature 
level. Shipments loaded closer to the compartment 
door might be exposed to lower temperatures than 
those loaded on the positions far from the compart-
ment door. Those however, might be subjected to the 
elevated temperatures due to the vicinity of the heat-
ing system source. During this phase in particular, the 
lower margin of the reliability interval of 95% is still 
around 12°C. This temperature was the exact value in 
which the phase before ended. Despite the fact that 



















2 part of the route
Temp [°C] = 16.2934+0.0592*x; 0.95 Predicted Interval
nd
Figure 3 – Temperature records obtained during storage at transit station Vienna International Airport
















3 part of the route
Temp [°C] = 34.2107-0.3481*x; 0.95 Predicted Interval
rd
Figure 4 – Temperatures recorded during the loading of the aircraft at the apron
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the least of the deviations occurred during this phase, 
the connection between the protection of the goods 
under defined temperature regime prior to loading and 
the flight has been noticed.
The next phase in the process comprises aircraft 
offload at destination airport and positioning in the 
adequate storage. Records obtained during this pro-
cess (Figure 6) show similar stability observed earlier 
(Figure 4 and 5). The lower margin of the reliability 
interval of 95% is still low at approximately +12°C. 
This can be explained as an occurrence deriving as a 
consequence from the exposure of the goods to low-
er temperatures during the previous phase. Only less 
significant changes (temperature deviation of 0.05°C 
per hour) have been recorded during this phase prob-
ably due to its short duration which is even below the 
error margin of the measuring devices. Yet the stan-
dard deviation is higher than the recorded one so far. 
Its value is 2.8°C which is a consequence of the dis-
persed input data.



















4 part of the route
Temp [°C] = 23.0905-0.1121*x; 0.95 Predicted Interval
th
Figure 5 – Temperature records obtained during the flight on Vienna – Washington route



















5 part of the route
Temp [°C] = 14.6325+0.0567*x; 0.95 Predicted Interval
th
Figure 6 – Aircraft offload at Washington Dulles International Airport
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FDA and customs clearance is observed as the sixth 
sequence in the process. This part of the distribution 
chain might be considered as the critical one due to 
the process duration uncertainty. The shipment stays 
at the final destination airport until those processes are 
completed. Although the average recorded values are 
within the limits similar to the phases observed earlier, 
deviations occurred with significant values. The aver-
age temperature value is +18.7°C but the deviations 
have peaks in the highest value so far. The minimal re-
corded temperature is +3°C and the standard devia-
tion value is 3.1°C. Observing the 90th hour where the 
standard deviation has its peak at 5.1°C, it might be 
concluded that this phase of the process represents 
the highest threat to the goods stability so far.
The final phase of the process consists in road 
transportation to the consignee’s warehouse. Accord-
ing to the gathered temperature values an improve-





















6 part of the route
Temp [°C] = 16.9849+0.0226*x; 0.95 Predicted Interval
th
Figure 7 – Storage at Washington Dulles International Airport



















7 part of the route
Temp [°C] = 14.6176+0.0463*x; 0.95 Predicted Interval
th
Figure 8 – Temperature recordings during road transportation from
the final destination airport to consignee's warehouse
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ment could be concluded compared to the previous 
phase; however, the standard deviation remains at 
high 2.4°C which is partly consequence of the dis-
persed input data. The average recorded temperature 
compared to the earlier phases is also elevated to 
+19.6°C. Deviations recorded are of a short duration 
and the lowest value reaches +12°C.
According to data available it might be concluded 
that the processes which include preparation of the 
shipment for the loading, flight and storage at final 
destination represent the highest risk to the tempera-
ture regime maintenance. The reason for this might 
be found in the complexity of this part of the distri-
bution channel. A number of different stakeholders 
appeared in this phase of the process thus bringing 
the complexity of the processes to a higher level. In 
order to determine the level of risk each of the distri-
bution phases is representing, the designed tempera-
ture mapping should be done for each infrastructure 
and transport means used. Mapping should be done 
for both winter and summer periods, thus marking 
the possible highest and lowest deviation tempera-
tures the goods might be exposed to. Based on the 
conducted temperature profiling, processes should be 
designed and qualified to address the issues related 
to regulatory aspect as well as to quality assurance for 
the product being shipped. Such qualified processes 
should be evaluated periodically and questioned for 
their compliance. The technical solutions available on 
the market which could be used to solve the tempera-
ture deviations are often not cost-effective and thus 
seldom used. In addition, simple and relatively cheap 
solutions (compared to other technical solutions avail-
able) such as thermal blankets for aircraft pallets are 
not qualified for the temperature regime maintenance 
and therefore not considered as the ultimate solution.
4. CONCLUSION
Pharmaceutical products are time and tempera-
ture sensitive. A requirement to maintain the con-
trolled temperature regime for certain pharmaceutical 
products during their distribution processes derive 
from the regulatory obligation stipulated by the nation-
al and international regulatory bodies. In general, GMP 
and GDP processes defined for these products com-
prise also defined storage and transportation condi-
tions. Transportation should be thus considered as an 
extended storage during which a defined temperature 
regime should be safeguarded. The risk evaluation of 
the multimodal process described in the paper offers 
possibility to contemplate on the quality of used trans-
portation means in terms of temperature stability. Cool 
trucking and controlled room storage where available 
could be considered as relatively stable distribution 
environment. Processes related to aircraft operations 
might be marked as less stable, as well as storage un-
der uncontrolled conditions during the FDA and cus-
toms clearance.
As a solution to overcome these shortcomings, the 
use of thermal protection in form of thermal blankets 
or even isolated unit load devices might be considered. 
This however should be subject to previous cost-effec-
tiveness evaluation. A separate research is suggested 
in this respect to show the effectiveness of one or the 
other technical solution used to prevent negative influ-
ence of temperature exposures. Particular focus could 
be put on the conditions to which shipments are sub-
jected during the flight in order to determine the level 
of risk related to this segment of the distribution chain.
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SAŽETAK 
 
VALORIZACIJA PRIJEVOZA FARMACEUTSKIH 
PROIZVODA ZRAČNIM PUTEM U UVJETIMA 
KONTROLIRANE SOBNE TEMPERATURE
Farmaceutska industrija je kao i zračni promet jedna od 
strogo reguliranih industrija današnjice. Prijevoz farmaceu-
tskih proizvoda u definiranim vremenskim i temperaturnim 
uvjetima predstavlja izazov koji proizlazi iz regulatornih 
obveza i potrebe osiguranja kvalitete proizvoda. Dobra 
proizvođačka praksa mora se primjenjivati kroz ukupan dis-
tributivni proces, no propisane regulatorne obveze još uvijek 
nisu u punoj mjeri na snazi. Prijevoz se mora promatrati kao 
produženo skladištenje, međutim stupanj usklađenosti pro-
cesa ovom pitanju izvor nalazi u ekonomskim umjesto regu-
latornim aspektima. Rad prikazuje razlike između definira-
nih zahtjeva održavanja kontrolirane sobne temperature i 
realnih tehnoloških mogućnosti u zračnom prometu danas. 
Primjeri pokazuju slučajeve temperaturnih devijacija tijekom 
transporta. Obrađeni prijevozni zadaci prikazuju devijacije u 
zadanom temperaturnom režimu po pojedinim fazama ob-
rade pošiljke. Predlažu se daljnja istraživanja koja za cilj ima-
ju valorizaciju svakog pojedinog dijela distributivnog lanca.
KLJUČNE RIJEČI
dobra distributivna praksa, regulatorna pitanja, kontrolirana 
sobna temperatura, temperaturne devijacije, kvalifikacija 
procesa
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11. Data logger is an instrument designed to measure tem-
perature, humidity, vibration or light exposure during 
distribution processes.
12. Unit load device, ULD - a pallet or container used for 
load on the aircraft. Part of aircraft equipment.
13. Values are rounded to the first higher value (e.g. 9 
hours and 50 minutes is rounded to 10 hours). The 
same is valid for cumulative values.
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